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Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important transcription factor in 
the defense against oxidative stress. Cumulative evidence has shown that oxidative 
stress plays a key role in the pathogenesis of Alzheimer’s disease (AD). Previous animal 
and clinical studies had observed decreased expression of Nrf2 in AD. However, the 
underlying regulation mechanisms of Nrf2 in AD remain unclear. Here, we used the DNA 
methyltransferases (Dnmts) inhibitor 5-aza-2′-deoxycytidine (5-Aza) to test whether 
Nrf2 expression was regulated by methylation in N2a cells characterizing by expressing 
human Swedish mutant amyloid precursor protein (N2a/APPswe). We found 5-Aza 
treatment increased Nrf2 at both messenger RNA and protein levels via downregulating 
the expression of Dnmts and DNA demethylation. In addition, 5-Aza-mediated upregu-
lation of Nrf2 expression was concomitant with increased nuclear translocation of Nrf2 
and higher expression of Nrf2 downstream target gene NAD(P)H:quinone oxidoreductas 
(NQO1). Our study showed that DNA demethylation promoted the Nrf2 cell signaling 
pathway, which may enhance the antioxidant system against AD development.
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inTrODUcTiOn
Alzheimer’s disease (AD) is a common neurodegenerative neurological disorder characterized 
pathologically by senile plaques, neurofibrillary tangles, and massive neuronal loss in the brain 
(Kumar et al., 2015). Numerous s1tudies have indicated that oxidative stress, an imbalance between 
free radicals and the antioxidant system, plays a significant role in the onset and progression of AD 
(Sultana et al., 2006; Zhao and Zhao, 2013). It has been reported that markers of oxidative stress were 
increased in the brains of AD patients (Williams et al., 2006). Evidence has also suggested that the 
activity of antioxidants is decreased in the early phase of AD (Cervellati et al., 2014). Because of the 
high concentration of polyunsaturated fatty acids and high oxygen consumptions in AD patients, 
those diseased brains were even more sensitive to oxidative stress (Farooqui and Horrocks, 1998). 
Thus, reducing oxidative damage in the brains could be a legitimate target for effective AD therapy.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a pivotal regulator of endogenous defense 
systems against oxidative stress, especially in the central nervous system (Yang et al., 2015). Nrf2 is 
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mainly sequestered in the cytoplasm by Kelch-like ECH associ-
ated protein 1 (Keap1). In response to reactive oxygen species, 
Nrf2 could be translocated from the cytoplasm to the nucleus and 
subsequently binds with antioxidant response element (ARE). 
This process can promote expression of a variety of antioxidant 
genes, such as superoxide dismutase (SOD), catalase (CAT), 
hemeoxygenase-1 (HO-1), and NAD(P)H:quinone oxidoreduc-
tas (NQO1), which exert cytoprotective effects against oxidative 
stress (Li and Kong, 2009). Additionally, the nuclear translocation 
of Nrf2 is paralleled with its total protein and messenger RNA 
(mRNA) expression levels (Kanninen et al., 2009; Zhang et al., 
2013). Despite that, previous animal and clinical studies had been 
consistently observing decreased Nrf2 level in hippocampus of 
AD (Ramsey et al., 2007; Tomobe et al., 2012; Farr et al., 2014). The 
underlying mechanisms of low expression of Nrf2 in AD patients 
remain largely unknown and need to be further investigated.
It is well established that DNA methylation affects gene expres-
sion (Momparler, 2005). DNA methylation blocks gene  expression, 
whereas demethylation with 5-Aza activates gene expression (Lu 
et al., 2013). 5-Aza, the DNA  methyltran ferases (Dnmts) inhibi-
tor, could demethylate DNA and alter gene  expression through 
downregulation of Dnmts or repression of Dnmts enzymatic 
activity (Juttermann et al., 1994; Qiu et al., 2002). 5-Aza is the 
first epigenetic drug that is approved by the Food and Drug 
Administration (FDA) for the treatment of myelodysplastic 
syndromes (MDS). Recently, Lu et al. (2013) found that the DNA 
methylation could regulate the Nrf2 level through modification 
of the first five CpG sites in prostate cancer.
Here, we used 5-Aza to investigate whether CpG methylation 
of the Nrf2 promoter could inhibit Nrf2 expression in the cellular 
model of AD. The aim of our study is to further explore if the expres-
sion of Nrf2 is regulated by DNA methylation and if upregulation of 
Nrf2 via DNA demethylation would promote the nuclear transloca-
tion of Nrf2 and the expression of its downstream gene NQO1.
MaTerials anD MeThODs
cell culture and Drug Treatments
Mouse neuroblastoma N2a cell stably expressing human Swedish 
mutation APP (N2a/APPswe) gene were kindly provided by Dr. 
Huaxi Xu (Burnham Institute for Medical Research, La Jolla, CA, 
USA). N2a/APPswe cells were maintained in 50% Dulbecco’s 
modified Eagle’s medium (DMEM), 50% OPTI-MEM plus 5% 
fetal bovine serum (Gibico, Carlsbad, CA, USA) in the presence 
of 150 μg/ml G418 and plated at a density of 2 × 107 in 75 cm2 
cell culture flasks. 5-Aza-2′-deoxycytidine (5-Aza) (Sigma, USA) 
was dissolved in DMSO according to the manufacturer’s protocol. 
Cells were seeded for 24 h, then treated with 0.1% DMSO, 3 μM 
5-Aza, and 5 μM 5-Aza for 72  h, maintained in a humidified 
incubator with 5% CO2 at 37°C. Cells of each group from three 
independent flasks were harvested for DNA, RNA, and protein 
analyses outlined below within each experimental procedure.
Total rna extraction and Quantitative 
real-Time Polymerase chain reaction
Total RNA was extracted from the cultured cells using the Trizol 
(Takara Bio, Japan) according to the manufacturer’s protocol. Then, 
first-strand cDNA was synthesized from total RNA by reverse 
 transcription (RT) using PrimeScript RT kit (TaKaRa, Japan), real-
time PCR was performed by Thermal Cycler Dice Real Time System 
(Thermo, USA) using SYBR PrimeScript PCR kit (Takara Bio, 
Japan). Quantitative real-time polymerase chain reaction (qPCR) 
was performed by an Eppendorf Mastercycler nexus instrument 
(Eppendorf, Germany) to quantify mRNA expression levels of Nrf2 
and NQO1. The following sequences for the Nrf2 and NQO1 primers 
were used: Nrf2 forward (5′-GTGCTCCTATGCGTGAATCC-3′) 
and reverse (5′-GCGGCTTGAATGTTTGTCTT-3′), NQO1 
forward (5′-GTTTCTGTGGCTTCCAGGTC-3′) and reverse 
(5′-CGTTTCTTCCATCCTTCCAG-3′). β-Actin was used as 
an internal control with sense (5′-GAGACCTTCAACACCCC 
AGC-3′) and antisense (5′-ATGTCACGCACGATTTCCC-3′) 
primers. Normalized values for specific gene mRNA expression 
were calculated as 2−ΔΔCT method.
Preparation of Protein lyses and Western 
Blotting
N2a/APPswe cells were treated with indicated concentrations 
of 5-Aza. After the 72  h of treatment, cells were harvested 
using RIPA buffer supplemented with a protease inhibitor 
cocktail (Sigma, St. Louis, MO, USA) to obtain whole protein 
lysate. In the case of nuclear protein extraction, the Nuclear 
and Cytoplasmic Protein Extraction Kit (BestBio, China) was 
used according to the manufacturer’s instructions. The protein 
concentrations of the cleared lysates were determined using 
the bicinchoninic acid (BCA) method (Pierce, Rockford, 
IL, USA). Equal quantities of protein (50  μg per lane) were 
electrophoresed on SDS-PAGE (Bio-Rad, CA, USA) under 
reducing conditions and then electrophoretically transferred 
onto the polyvinylidene difluoride (PVDF) membranes 
(Millipore, USA) followed by blocking with 5% BSA for 1.5 h. 
The PVDF membranes were incubated overnight at 4°C probed 
with primary antibodies: Nrf2 (Abcam, USA; 1:1,000), NOQ1 
(Genetex, USA; 1:1,000), Dnmt1, Dnmt3a, and Dnmt3b (Santa 
Cruz, CA, USA; all 1:400), β-actin (Santa Cruz, CA, USA; 
1:3,000), and Lamin B (Beijing TDY Biotech, China; 1:3,000). 
β-Actin or Lamin B was used as a loading control. After wash-
ing with TBST, membranes were then incubated with horse-
radish peroxidase-conjugated secondary antibody (BOSTER, 
Wuhan, China, 1:2,000). The immunoreactive protein bands 
were detected with a Chemiluminescence Luminal reagent 
(Keygen, China) and the intensity of the bands was analyzed 
with Quantity One (Bio-Rad, USA).
immunofluorescence staining
N2a/APPswe cells treated with or without 5-Aza were fixed with 
4% paraformaldehyde for 15  min at room temperature on the 
slides and followed by a rinse with phosphate-buffered saline 
(PBS) three times for 15 min. After washing, cells were incubated 
with 0.3% Triton for 15  min at room temperature and then 
blocked with 5% BSA for 30 min. The cells were incubated with 
Nrf2 antibody at 1:100 (Abcam, USA) overnight at 4°C. Next day 
the cells were washed three times in PBS for 15 min. Then, the 
cells were incubated with goat anti-rabbit conjugated to DyLight 
549 secondary antibody at 1:200 (Abbkine, USA) for 30 min at 
FigUre 1 | Upregulation of mrna and protein levels of nrf2 by 5-aza treatment in n2a/aPPswe cells. N2a/APPswe cells were treated with 0 μM 5-Aza 
(control), 0.1% DMSO, 5-Aza (3 and 5 μM) for 72 h. The expressions of Nrf2 and β-actin mRNA were measured by Q-PCR using total RNA from N2a/APPswe cells. 
β-Actin was assessed as a loading control (a). The protein expressions of total Nrf2 (T-Nrf2) and β-actin were measured by Western blot analysis using lysates from 
N2a/APPswe, normalized to β-actin expression (B). All data were represented as a mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01.
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37°C. Later, the cells were washed three times in PBS for another 
15 min and then stained with DAPI (Beyotime, Dalian, China) 
for 3  min at room temperature. Finally, cells were washed in 
PBS for 15  min and observed with a Confocal Laser-scanning 
Microscope (A1R, Nikon, Japan).
Bisulfite-sequencing Pcr
Genomic DNA was isolated from 0.1% DMSO and 5 μM 5-Aza 
treated N2a/APPswe cells using the DNeasy Tissue Kit (QIAGEN, 
Valencia, CA, USA). The bisulfite conversion was carried out by 
Methylamp DNA Modification Kit (Epigentek, Brooklyn, NY, 
USA) with 2 μg of genomic DNA by the manufacturer’s instruc-
tions. The converted DNA was amplified by PCR using Platinum 
BluePCR SuperMix (Invitrogen, Grand Island, NY, USA) and 
primers that amplify the first five sites located between −1226 
and −1175 of the murine Nrf2 gene with the translational 
start site defined as +1. The sequences of the primers were as 
follows:  5′-GAGTTATTTTAAGTATTTTAGATATTTTG-3′ 
(sense) and 5′-ATACTCAAACACCTCTACCCC-3′ (anti-
sense). PCR products were separated on agarose gels that 
were excised for the DNA fragment containing the first five 
CpG sites for being cloned into the pUC18-T vector (Biodee, 
Beijing, China). Plasmid DNA from at least 10 colonies per 
each group was purified using the QIAquick PCR purification 
kit (QIAGEN, Valencia, CA, USA) and sequenced by Sangon 
Biotechnology.
statistical analysis
All results are expressed as means ± SD. Post hoc tests following 
the one-way ANOVA analyses were used to determine the differ-
ences between multiple groups. The chi-square test was used to 
analyze the first five CpG site methylation rates of Nrf2 gene. A 
value of P < 0.05 was considered statistically significant.
resUlTs
5-aza increases mrna and Protein 
expression of nrf2 in n2a/aPPswe cells
To investigate the effect of DNA methylation against Nrf2 
expression in N2a/APPswe cells, the cells were treated with 
0 μM 5-Aza (control), 0.1% DMSO, 5-Aza (3 and 5 μM) for 72 h. 
The relatively low Nrf2 mRNA and protein levels were found 
in control group. By contrast, the mRNA and protein of Nrf2 
were significantly increased by 5-Aza treatment (Figures 1A,B). 
These findings suggest that 5-Aza can increase the expression 
of Nrf2.
5-aza suppresses Dnmts Protein 
expression
Because DNA methylation occurs at the 5′ position of the cytosine 
residue within CpG dinucleotides through the addition of a methyl 
group by DNA methyltransferases (Dnmts), including Dnmt1, 
FigUre 3 | The first five cpg sites are specifically demethylated by 
5-aza treatment. N2a/APPswe cells were treated with 0.1% DMSO, 5 μM 
5-Aza for 72 h. The methylation patterns of the first five CpG sites of 
promoter Nrf2 gene in N2a/APPswe cells were performed using bisulfite 
genomic sequencing (BGS) as described in Section “Materials and Methods.” 
Black circles indicate methylated CpGs, and open circles indicate 
unmethylated CpGs. The first five CpGs were hypermethylated in N2a/
APPswe cells, which were treated with 0.1% DMSO (98% methylated) (a) 
and cells treated with 5 μM 5-Aza for 72 h (78% methylated) (chi-square test, 
P < 0.05) (B).
FigUre 2 | 5-aza suppresses Dnmts protein expression. N2a/APPswe cells were treated with 0 μM 5-Aza (control), 0.1% DMSO, 5-Aza (3 and 5 μM) for 72 h. 
The protein expressions of Dnmt1, Dnmt3a, Dnmt3b, and β-actin were measured by Western blot. β-Actin was assessed as a loading control. All data were 
represented as a mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01.
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Dnmt3a, and Dnmt3b in mammals (Subramaniam et al., 2014). Our 
results showed that the Dmnts expression has been reduced by appli-
cation of 5-Aza in N2a/APPswe cells (Figure 2), indicating that 5-Aza 
can deprive of Dnmts activity, leading to the lower DNA methylation.
The First Five cpg sites in the nrf2 
Promoter are specifically Demethylated 
by 5-aza Treatment
One hundred fifty CpG sites ranging from −1226 to +1240 were 
identified on the murine of Nrf2 genomic sequence by sequence 
analysis. The CpG island includes the murine Nrf2 promoter, the 
first exon, and part of the first intron. Yu et al. (2010) proposed that 
the first five CpG sites of Nrf2 (−1226 to −1175) play a critical role 
in methylation-dependent suppression of Nrf2 promoter activity 
that designates the initiation site of translation as +1. To identify 
whether the first five CpG sites responsible for Nrf2 expression in 
N2a/APPswe cells, bisulfite sequencing was performed on extracted 
DNA from N2a/APPswe cells that were incubated with or without 
5-Aza treatment to quantitatively analyze the methylation levels of 
first five CpG sites in Nrf2 gene. Ten clones were selected to analyze 
for each CpG site. We found that 49 out of 50 (98%) CpG sites 
were methylated in basal N2a/APPswe cells without 5-Aza treat-
ment (Figure 3A). Five micromolar of 5-Aza was then selected to 
treat N2a/APPswe cells with regard to its significant upregulation 
of Nrf2 expression (Figures 1A,B). Results have shown that Nrf2 
promoter methylation decreased to 39 out of 50 (78%) in the first 
five CpG sites after treated with 5  μM 5-Aza (chi-square test, 
P < 0.05) (Figure 3B), indicating that the first five CpG sites of 
Nrf2 promoter have been demethylated by 5-Aza treatment.
5-aza Promotes the nuclear Translocation 
of nrf2 and increases mrna and Protein 
expression levels of nrf2 Downstream 
gene
To determine whether the upregulation of Nrf2 via DNA dem-
ethylation could promote the activation of Nrf2, the nuclear 
FigUre 4 | 5-aza promotes the nuclear translocation of nrf2 in n2a/aPPswe cells. N2a/APPswe cells were treated with 0 μM 5-Aza (control), 0.1% DMSO, 
5-Aza (3 and 5 μM) for 72 h. The protein expressions of N-Nrf2 (nucleus protein of Nrf2) and Lamin B were measured by Western blot using nuclear protein from 
N2a/APPswe cells. Lamin B was assessed as a loading control (a). Immunofluorescence staining was used to observe the distribution of Nrf2 (B). N2a/APPswe 
cells were treated with 5 μM 5-Aza for 72 h and labeled with anti-Nrf2 antibody (red) and DAPI (blue), APPswe were labeled with GFP (green). Scale bar 50 μm. All 
data were represented as a mean ± SD of three independent experiments. **P < 0.01.
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translocation of Nrf2 induced by 5-Aza was further assessed. 
We found that 5  μM of 5-Aza can significantly increase the 
nuclear translocation of the Nrf2 protein in N2a/APPswe cells 
(Figure 4A). This finding was further confirmed by immunofluo-
rescence staining (Figure 4B). To determine how upregulation 
of Nrf2 influences the oxidative stress status, one of the Nrf2 
downstream target genes, NQO1, was selected for quantification. 
We found that the mRNA and protein expressions of NQO1 were 
significantly increased in 5-Aza treated group compared with that 
in control group in N2a/APPswe cells (Figure 5).
DiscUssiOn
Cumulative evidence has demonstrated that oxidative stress is 
inextricably linked with several major pathological processes in 
AD (Sheng et al., 2009; Clausen et al., 2012; Porcellotti et al., 2015). 
Nrf2, a pivotal regulator of endogenous defense systems against 
oxidative stress, is decreased in AD brain tissue (Kanninen et al., 
2009). In previous studies, Yu et al. (2010) demonstrated DNA 
methylation in the first five CpG sites of Nrf2 gene silenced its 
transcriptional activity. Here, by using the N2a/APPswe cell lines 
characterized by oxidative stress injury, we found Nrf2 expres-
sion is regulated by DNA methylation. 5-Aza treatment can lead 
to the increase in the mRNA and protein expressions of the Nrf2 
gene. Furthermore, 5-Aza specifically decreased the expression 
of Dnmt1, Dnmt3a, and Dnmt3b and demethylated the first 
five CpG sites in the promoter of Nrf2. Our results suggest that 
the first five CpG sites in the promoter may play an important 
role in Nrf2 expression via an epigenetic regulation of DNA 
methylation in AD cellular model. In addition, we found 5-Aza 
can promote the nuclear translocation of Nrf2 and increase the 
mRNA and protein expressions of NQO1 in N2a/APPswe cells. 
Our findings strongly suggest that DNA demethylation may be 
an effective pathway to reactivate the Nrf2 cell signaling in AD 
cellular model.
The methylation of CpG dinucleotides at the 5′ position on the 
pyrimidine ring to form 5-methylcytosine (5-mC) disrupts the 
cellular transcriptional machinery and results in gene silencing. 
In contrast, DNA hypomethylation is associated with upregula-
tion of gene expression (Bhutani et  al., 2011). Previous studies 
demonstrated that aberrant DNA methylation of genes was 
associated with initiation and progression of AD (Adwan and 
Zawia, 2013). In a recent study, Fleming et al. (2012) found that 
DNA hypomethylation may account for the upregulation of three 
well-established AD-related genes (APP, BACE1, and PS1). DNA 
hypermethylation of CpG islands in the promoter region of genes 
is associated with transcriptional silencing (Subramaniam et al., 
2014). Our results showed that, a lower Nrf2 level and hyper-
methylation of the first five CpG sites were observed in untreated 
N2a/APPswe cells, indicating that hypermethylation was closely 
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related to the low Nrf2 gene expression. Demethylation of Nrf2 
gene promoter CpG sites could restore the gene expression.
In our study, we investigated whether 5-Aza, a Dnmts 
inhibitor, could reactivate the expression of Nrf2 gene in N2a/
APPswe cells. The results showed that 5-Aza treatment can 
restore the expression of this gene. We then tested the expres-
sion of Dnmt1, Dnmt3a, and Dnmt3b that all mediate the 
effects of 5-Aza in mammals (Liao et al., 2015) and found the 
decreased expression of Dnmts in 5-Aza treated N2a/APPswe 
cells. Our results corroborate with previous findings that 5-Aza 
activated gene expression in a methylation-dependent manner 
(Schmelz et al., 2005). Using bisulfite sequencing, we found that 
the first five CpGs in Nrf2 promoter were hypermethylated in 
solvent control group but not in 5-Aza treated group (98 vs. 
78%). Combined with a previous study that methylation of the 
first five CpGs can significantly suppress the transcriptional 
activity of Nrf2 in mouse (Yu et  al., 2010), we propose that 
5-Aza indeed affects expression of Nrf2 through repression of 
Dnmts expression in N2a/APPswe cells, demonstrating that 
DNA methylation can regulate the expression of Nrf2 in AD 
cellular model.
In the present work, we observed that Nrf2 could not be 
translocated to the nucleus or was less antigenically available 
in AD neuronal nuclei. This finding is in accordance with a 
report that Nrf2 does not respond to the oxidative stress in AD 
(Ramsey et al., 2007). Translocation of Nrf2 into the nucleus is 
also  regulated by phosphorylation via several kinases including 
phosphoinositol-3 kinase (PI3K), extracellular signal-regulated 
protein kinase (ERK), protein kinase C (PKC), and pancreas-
enriched kinase (PERK) (Bryan et al., 2013). Interestingly, in this 
study, we found that increasing both Nrf2 mRNA and protein 
levels by DNA demethylation resulted in remarkable increases of 
nucleus protein of Nrf2 (N-Nrf2). In addition, the 5-Aza treated 
N2a/APPswe cells also showed more nuclear immunofluores-
cence than that in solvent control group using immunofluores-
cence staining. Vargas et al. (2005) also reported that increasing 
both Nrf2 mRNA and protein levels by fibroblast growth factor 
family could contribute to activation of Nrf2 and induction of 
ARE-driven genes. These data indicate that the activity of Nrf2 
is related to its total protein and mRNA expression levels. Taken 
together, these findings suggest that the regulation of Nrf2 gene 
has multiple pathways.
NQO1, an antioxidant enzyme, is one of the target genes of 
Nrf2 and plays a key role in maintenance of cellular redox state 
by reduction of various quinones and by prevention of reactive 
oxygen species accumulation (Zhou and Seeley, 2014). Here, we 
found that 5-Aza can increase the mRNA and protein expres-
sion levels of NQO1, which correlates with the increased total 
FigUre 5 | 5-aza increases mrna and protein expression levels of nrf2 downstream gene nQO1. N2a/APPswe cells were treated with 0 μM 5-Aza 
(control), 0.1% DMSO, 5-Aza (3 and 5 μM) for 72 h. The protein expressions of NQO1 and β-actin were measured by Western blot analysis using total protein from 
N2a/APPswe. β-Actin was assessed as a loading control. All data were represented as a mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01.
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